179 related articles for article (PubMed ID: 15564511)
1. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
[TBL] [Abstract][Full Text] [Related]
2. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
[TBL] [Abstract][Full Text] [Related]
4. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.
Armbruster C; Stiegler GM; Vcelar BA; Jäger W; Köller U; Jilch R; Ammann CG; Pruenster M; Stoiber H; Katinger HW
J Antimicrob Chemother; 2004 Nov; 54(5):915-20. PubMed ID: 15456731
[TBL] [Abstract][Full Text] [Related]
5. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
[TBL] [Abstract][Full Text] [Related]
6. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
Quakkelaar ED; Bunnik EM; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Schuitemaker H
Virology; 2007 Jul; 363(2):447-53. PubMed ID: 17355886
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
8. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
Jülg B; Goebel FD
Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
[TBL] [Abstract][Full Text] [Related]
9. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
[TBL] [Abstract][Full Text] [Related]
11. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
12. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
Ou W; Lu N; Yu SS; Silver J
J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.
Utachee P; Jinnopat P; Isarangkura-Na-Ayuthaya P; de Silva UC; Nakamura S; Siripanyaphinyo U; Wichukchinda N; Tokunaga K; Yasunaga T; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
Microbes Infect; 2009 Mar; 11(3):334-43. PubMed ID: 19136072
[TBL] [Abstract][Full Text] [Related]
14. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
[TBL] [Abstract][Full Text] [Related]
15. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
[TBL] [Abstract][Full Text] [Related]
16. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
17. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
[TBL] [Abstract][Full Text] [Related]
18. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
19. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
Wolbank S; Kunert R; Stiegler G; Katinger H
J Virol; 2003 Apr; 77(7):4095-103. PubMed ID: 12634368
[TBL] [Abstract][Full Text] [Related]
20. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.
Kitabwalla M; Ferrantelli F; Wang T; Chalmers A; Katinger H; Stiegler G; Cavacini LA; Chou TC; Ruprecht RM
AIDS Res Hum Retroviruses; 2003 Feb; 19(2):125-31. PubMed ID: 12639248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]